Scripps team finds erucamide protects retina via immune cells — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Scripps Research scientists, working with UC San Diego and the Lowy Medical Research Institute, identified erucamide, a fatty acid amide whose levels drop sharply as photoreceptors deteriorate in retinal disease.
- Restoring erucamide via porous silicon nanoparticles activated CD11b+ myeloid immune cells through a protein called TMEM19, leading to neurovascular stabilization and slower degeneration in preclinical models.
- Senior author Martin Friedlander said the retina "doesn't simply deteriorate; in fact, it actively responds to injury," framing erucamide as a signaling molecule that coordinates that protective response.
- First author Guoqin Wei noted erucamide works by engaging the surrounding tissue environment rather than targeting photoreceptors directly — a shift in perspective the team says could matter for future degenerative retinal disease treatments.
- The study, published June 19, 2026 in Nature Neuroscience, was prompted by an earlier finding that transplanted stem cell-derived retinal cells slowed degeneration even after those cells had disappeared.
- Co-author Dale Boger, the Richard and Alice Cramer Professor of Chemistry at Scripps Research, called the observed decline in erucamide "a pivotal moment," suggesting the molecule may influence disease rather than merely reflect it.
- Turning erucamide into a treatment will require solving formulation hurdles, since its hydrophobic nature means it clumps when injected — which is why the team relied on nanoparticle carriers to keep it stable and evenly distributed inside the eye.
Why it matters: Erucamide targets the neurovascular unit rather than dying photoreceptors, opening a potential new therapeutic route for diseases like retinitis pigmentosa, diabetic retinopathy and age-related macular degeneration, where treatment options remain limited. The work is preclinical and challenges remain around hydrophobic formulation, but it reframes retinal disease as a process the eye already partly fights, not one it passively undergoes.
Ask SkimNews
